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Abstract
Background: Balance, mobility impairments and falls are problematic for people with multiple sclerosis (MS). The
“Balance Right in MS (BRiMS)” intervention, a 13-week home and group-based exercise and education programme,
aims to improve balance and minimise falls. This study aimed to evaluate the feasibility of undertaking a multi-
centre randomised controlled trial and to collect the necessary data to design a definitive trial.
Methods: This randomised controlled feasibility study recruited from four United Kingdom NHS clinical neurology
services. Patients ≥ 18 years with secondary progressive MS (Expanded Disability Status Scale 4 to 7) reporting more
than two falls in the preceding 6 months were recruited. Participants were block-randomised to either a manualised
13-week education and exercise programme (BRiMS) plus usual care, or usual care alone.
Feasibility assessment evaluated recruitment and retention rates, adherence to group assignment and data
completeness. Proposed outcomes for the definitive trial (including impact of MS, mobility, quality of life and falls) and
economic data were collected at baseline, 13 and 27 weeks, and participants completed daily paper falls diaries.
Results: Fifty-six participants (mean age 59.7 years, 66% female, median EDSS 6.0) were recruited in 5 months; 30
randomised to the intervention group. Ten (18%) participants withdrew, 7 from the intervention group. Two additional
participants were lost to follow up at the final assessment point. Completion rates were > 98% for all outcomes apart
from the falls diary (return rate 62%).
After adjusting for baseline score, mean intervention—usual care between-group differences for the potential primary
outcomes at week 27 were MS Walking Scale-12v2: − 7.7 (95% confidence interval [CI] − 17.2 to 1.8) and MS Impact
Scale-29v2: physical 0.6 (CI − 7.8 to 9), psychological − 0.4 (CI − 9.9 to 9). In total, 715 falls were reported, rate ratio
(intervention:usual care) for falls 0.81 (0.41 to 2.26) and injurious falls 0.44 (0.41 to 2.23).
Conclusions: Procedures were practical, and retention, programme engagement and outcome completion rates
satisfied a priori progression criteria. Challenges were experienced in completion and return of daily falls diaries.
Refinement of methods for reporting falls is therefore required, but we consider a full trial to be feasible.
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Key messages on feasibility
(i) What uncertainties existed regarding feasibility? It
was unknown whether the recruitment strategies and
processes would be effective, and whether
participants would be able to maintain engagement
with the trial and the BRiMS programme. There
were also uncertainties about the choice of a primary
outcome for a full effectiveness trial, and the methods
used for collecting prospective falls data.
(ii) What are the key findings on feasibility from this
study? The trial methods were feasible and effective in
recruiting and retaining participants, although some
changes to the BRiMS programme were indicated to
reduce attrition. Most outcome measures had
satisfactory completion; however, there were
challenges in the methods of collecting falls data.
(iii)What are the implications of the feasibility findings
on the design of the main study? The findings
indicate that a large-scale trial is feasible; however,
refinement of falls reporting methods and develop-
ment of BRiMS programme delivery methods are
recommended prior to progressing further.
Background
Multiple sclerosis (MS) is an incurable, unpredictable but
typically progressive, life-long, neurological condition, af-
fecting approximately 100,000 people in the UK (UK) [1]. It
is the most common cause of neurological disability in
young adults. Although most people start with a relapsing-
remitting (RR) disease course, approximately two-thirds
move to a progressive phase, with a steady rise in the pro-
portion of progressive cases as the disease advances.
Within approximately 15 years of diagnosis, an esti-
mated 50% of people are unable to walk unaided, and
eventually 25% are dependent on a wheelchair [2]. An
important contributor to this is impaired balance, which
is reported by approximately 75% of people with MS [3].
Mobility is more compromised in those with secondary
progressive MS (SPMS) compared to RR MS [4]. Our
previous work suggests that falls may be an early marker
of mobility deterioration associated with disease progres-
sion [5]. Rehabilitation interventions which improve bal-
ance and mobility, and therefore decrease the risk of
falls, may slow this deterioration, providing a persuasive
argument for ensuring this should be a clinical priority.
With only limited medical interventions available for this
patient group, rehabilitation programmes are considered
key to management but currently lack a robust evidence
base [6].
In partnership with service users, providers of re-
habilitation services, other key stakeholders (including
service commissioners) and international collabora-
tors, our ongoing research programme has systematic-
ally developed ‘Balance Right in MS’ (BRiMS), an
innovative 13-week evidence-based, user-focused,
manualised, self-management programme, designed to
improve safe mobility and reduce falls for people with
MS [5, 7, 8]. The programme includes personalised
education and exercise and motivation components,
designed to address modifiable fall risk factors, and
enable self-management by use of mobility, safety and
falls risk management strategies.
Aim
The overall aim of this study was to evaluate the feasibility
of undertaking a multi-centre randomised controlled trial
(RCT) to compare BRiMS plus usual care with usual care
alone, and to collect the necessary data to design a defini-
tive trial. The study objectives were to determine:
1. Feasibility:
 Suitability, utility and acceptability of the study
procedures
 Appropriateness of eligibility criteria,
 Viability of recruitment and randomisation
procedures,
 Retention rates,
 Participant engagement throughout the study,
 Adverse events.
2. Potential definitive trial outcomes:
 The selection of primary and secondary outcome
measures including:
 Their characteristics and rates of completion i.e.
baseline scores, distributional properties standard
deviations,
 Responsiveness and to help determine the
sample size for the RCT.
3. Health economics objectives:
 Estimates of resource use and related costs
associated with delivery of the BRiMS
intervention
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Methods
The study was undertaken according to the methods detailed
in our protocol [9], which are briefly summarised below.
Study design
This was a pragmatic, mixed-methods, multi-centre,
feasibility, individually randomised, group treatment
RCT, with blinded outcome assessment and embedded
process evaluation.
Participants
The target population was English-speaking men and
women, aged ≥ 18 years, with a confirmed diagnosis of
SPMS (Expanded Disability Status Scale (EDSS) 4-7 in-
clusive), who reported having walking difficulties and
more than two falls in last 6 months. People were ex-
cluded if they
 had ever had previous treatment with alemtuzumab;
 were within 6 months of ceasing natalizumab; or
within 3 months of ceasing any other MS disease-
modifying drug;
 reported a relapse within the last month as defined:
“the appearance of new symptoms, or the return of
old symptoms, for a period of 24 h or more—in the
absence of a change in core body temperature or
infection”) [10];
 had been referred to a falls management programme
within the previous 6 months, or
 were participating in a concurrent trial.
Recruitment
The study recruited from four UK NHS clinical neurology
services. Potential participants were identified through
local and national advertising, adoption on to the local
NIHR Clinical Research Network portfolio and via the
caseload of local MS clinicians. Due to the nature of the
group-based intervention and to facilitate randomisation,
participants were recruited in blocks of 8–12 individuals
(for full details, refer to the study protocol [9]).
Study procedures
The participant pathway is detailed in Fig. 1. Site-based
research therapists screened potential participants by
telephone interview. Final eligibility checking, informed
consent and baseline measures were undertaken at a sin-
gle face-to-face meeting at a local healthcare venue, no
more than 2 weeks prior to the pre-scheduled random-
isation date for each BRiMS delivery. Randomisation was
undertaken via a secure web-based system by staff from
the UK Clinical Research Collaboration registered Penin-
sula Clinical Trials Unit who were not involved in the
delivery of the study. Participants were randomised in
block sizes of 8–12. Within each block, participants were
individually randomised to BRiMS plus usual care
(BRiMS) or usual care only on a 1:1 basis and informed
of this allocation by email.
Participants were followed-up on two occasions: at 13
weeks (± 1 week) and 27-weeks (± 1 week) following
randomisation.
Staffing
BRiMS sessions were delivered by trained treating physio-
therapists [11]. Research assessments were undertaken by
research physiotherapists who were aware of the study
aims but were blinded to individuals’ allocated group.
Interventions (see Fig. 2)
In addition to usual care, participants allocated to the
BRiMS programme were asked to undertake a home ex-
ercise and falls prevention education programme. This
aimed to support participants to achieve a minimum of
120 min of individualised, progressive, gait, balance and
functional training per week, and to complete four edu-
cation packages (focussing on enabling the development
of falls prevention strategies and self-efficacy) over the
13 weeks. Participants were invited to attend two one-
to-one sessions: an initial assessment and goal setting
session at local NHS/ university physiotherapy facilities,
and a home visit to explain and demonstrate use of the
online resources, support the home exercise programme
and to problem solve any issues. Ongoing support was
provided by online resources, a paper-based manual, bi-
weekly reviews of participants’ online exercise logs by
therapy staff and three, 2-h group sessions at local NHS/
university physiotherapy facilities for peer support,
group exercise and interactive learning activities over
the course of the programme.
Participants allocated to the usual care group continued
to receive their usual clinical input. Although usual care
varies across the country [12], it rarely involves regular on-
going physiotherapy intervention on either an individual
or a group basis. With the exception of the study assess-
ments, they were not asked to attend any additional visits
or sessions. Data on the nature/frequency of usual care for
all participants was captured via a resource use question-
naire at each assessment time-point.
Sample size
The target sample size was 60 participants across four UK
sites in two regions (40 in the South West of England and
20 in Ayrshire, Scotland) to be recruited over 6 months.
This would allow estimation of the overall retention rate
with precision (using a 95% confidence interval) of at least
± 13%, improving to a ± 10% precision if the 27-week
follow-up rate was around 80% [13, 14]. Assuming a non-
differential follow-up rate of 80%, this recruitment target
was anticipated to provide follow-up data on a minimum of
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24 participants in each of the allocated groups, sufficient to
calculate estimates of variability for the proposed outcome
measures to inform indicative sample size calculations for
the definitive trial.
Outcomes
Outcome measures appropriate to each of the study objec-
tives are listed in Table 1, with further detail included in
Additional file 1. Potential primary and secondary outcome
measures were chosen based on their relevance to the aims
of the BRiMS programme and that there was psychometric
evidence to support their use. Although the reduction of
accidental falls was a key aim of BRiMS, falls rates (calcu-
lated from prospectively completed falls diaries, returned
every 2 weeks) were considered a potential secondary rather
than primary outcome, due to concerns about the reliability
and validity of self-report falls diary data [15]. Instead a psy-
chometrically robust mobility measure was chosen as a
Fig. 1 Participant pathway
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potential primary outcome, on the basis that this was likely
to reflect changes in “safe” mobility which was a key goal of
the BRIMS programme”
Progression criteria
A number of progression criteria were pre-defined in
discussion with the Trial Steering Committee (TSC):
1. A minimum of 80% recruitment within the planned
6-month recruitment window
2. A minimum of 80% participants randomised to
BRiMS engaging with the programme (defined as
attending the initial face-to-face clinic visit and
home visit).
3. A minimum of 80% completion rate of at least one
of the proposed primary outcome measures
amongst participants attending the planned primary
end-point of 27 (± 1 week).
4. That the total resource estimated to conduct the
definitive trial is within a level that is likely to
attract funding.
Data analyses
A detailed statistical analysis plan was approved by the
TSC prior to database lock. The statistical analyses were
undertaken using StataSE version 14, supplemented
where required by R [25].
Analyses were undertaken on a modified Intention
To Treat (mITT) basis, with additional analysis of the
falls data as outlined below, and in accordance with
guidelines for pilot and feasibility trials [26]. Descriptive
statistics were used to summarise patient eligibility,
recruitment, allocation and retention, demographic and
clinical characteristics, outcome measures and their
completeness. Where appropriate, parameter estimates
(e.g. between-group differences, both unadjusted and
adjusted for baseline values where available) are pre-
sented with confidence intervals but no formal hypo-
thesis testing was undertaken [26]. Outliers were
identified and reported but not removed from the de-
scriptive statistics unless otherwise stated. For the vali-
dated patient reported outcome measures, MS Walking
Scale-12v2.0 [16] (MSWS-12v2), MS Impact Scale-
29v2.0 [16, 18, 19] (MSIS-29v2) and Falls Efficacy Scale
(international) [23] (FESi), established methods for im-
puting missing item-level data were implemented when
the minimum requirements were met [27–29]. A vali-
dated imputation method was not available for the
Community Participation Indicators [24] score and so
summaries for this score are based on complete data
only.
Rates of falls and injurious falls were calculated per
person per year, using two different methods: (a) the
“mITT” analysis assumed that if a participant did not
complete or return a diary entry for a particular day,
they did not fall (i.e. missing values were replaced
with zeroes/no fall); (b) the “Observed” analysis used
only the completed diary data. The rates were com-
pared between allocated groups using unadjusted rate
ratios (intervention: usual care), with bootstrapped
confidence intervals.
Mean health state values and quality adjusted life-
years (QALY) estimates used in the health economics
analysis were based on the EQ5D-3L [30] derived from
the EQ-5D-5L health states and the MS-specific prefer-
ence based measure, the MSIS-8D [31] (derived from
participant reports for the MSIS-29) collected through-
out the study. The QALY combines length and quality-
of-life in a single outcome measure. Each year of life is
weighted by quality-of-life during that time. Quality-of-
life is represented by QALY weights on a scale from zero
(equivalent to being dead) to one (perfect health). QALY
weights can also be negative, representing quality-of-life
thought worse than being dead. A higher number of
QALYs indicates a better health outcome. NICE advice
is to use the EQ5D-3L rather than the EQ5D-5L [32];
therefore, the EQ5D-5L was mapped to the EQ5D-3L
using the “cross walk” technique [30].
Fig. 2 BRiMS programme delivery plan. SAE: serious adverse reactions (as classified by the study principle investigator/ chief investigator (see
study protocol for details) [9]. Only a sub-group of participants were invited to participate in the qualitative interview.** One participant did not
complete baseline data for the EQ5D-5L potential primary outcome
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Results
Feasibility outcomes
Recruitment, randomisation, retention and engagement
(Fig. 3)
Recruitment Of the 232 subjects screened over 5
months, 44 specifically declined and a further 20 were
deemed ineligible on screening, leaving 56 consented
participants (satisfying progression criterion 1). The
main reasons for individuals declining to participate
were the time commitment (n = 16/44, 36%), and lack a
computer or tablet access /poor IT literacy (n = 14/44,
32%). Despite using a range of recruitment procedures,
thirty-seven (66%) of the 56 consented participants were
recruited via personal approach by research support staff
or local clinicians.
Randomisation Randomisation procedures were imple-
mented successfully, resulting in the allocation of 30
participants to the BRiMS plus usual care group, and 26
to the usual care group.
Table 1 Outcome measures and data collection schedule [16–24]
*After randomisation
aParticipants returned data prospectively reporting falls and related injuries, adverse events and any new/worsening symptoms every 2 weeks for the duration of
the study using pre-formatted paper diaries
bAt each research assessment visit, participants had an accelerometer (ActivPALTM Monitor) attached to their thigh. Participants were provided with instructions
for removal of the device and a reply paid envelope to return it to the research therapist after 1 week
d Collected via a resource use questionnaire
Gunn et al. Pilot and Feasibility Studies             (2021) 7:2 Page 6 of 15
Retention The overall retention rate at week 27 was
79% (95% CI 66 to 88%); there was a higher withdrawal
rate in the intervention group.
Programme engagement Twenty-seven of the 30 par-
ticipants (90%) allocated to the intervention group met
the criteria for engagement with the programme (satisfy-
ing progression criterion 2).
Safety and serious adverse events (SAEs) There were
nine reports of SAEs from seven individuals over the study
period (two usual care, five intervention). The two individuals
who each reported two SAEs were in the intervention group.
Despite participants all being classified with SPMS, four of the
SAEs were reported to relate to MS relapses, the others to un-
related medical problems (n = 1) or falls with injuries requir-
ing hospitalisation (n = 3; 2 intervention, 1 usual care). No
SAE was assessed to be related to the BRiMS intervention.
Fig. 3 CONSORT flow diagram
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Trial outcome objectives
Outcome measure completion rates
At each assessment, the completion rate of each out-
come measure was in excess of 98% (satisfying progress-
sion criterion 3). However, the overall return rate for the
patient-reported falls diary was 62%. There was also in-
complete recording within the diaries that were
returned, meaning that data were available for 58% of
the expected total number of days for falls, and 41% of
the expected total for injurious falls. The diary return
rate was different between allocated groups (54% BRiMS,
78% usual care).
Demographic and clinical characteristics at baseline
Table 2 details summary statistics of the participants’
baseline characteristics by allocated group and for the
total sample: For full details, see final study report
[11]. The groups were broadly comparable at baseline,
although there were differences in disease severity
(EDSS), anxiety/depression and cognition (symbol
digit modalities test).
Outcomes
Table 3 shows summary statistics together with the sim-
ple between-group mean differences, mean differences
after adjustment for corresponding baseline score, and
the indicative minimal clinically important difference
(MCID), where available, for the proposed primary out-
come measures. Baseline scores indicate significant mo-
bility impairments and falls-related concern. On average,
participants in the intervention group scored worse than
those in the usual care group at baseline. The adjusted
mean differences in the MSWS-12v2 and the MSIS-29v2
indicate that the BRiMS group improved more at 15
weeks relative to the usual care group; the adjusted
between-group difference for MSWS-12v2 (physical)
exceeded the MCID [21] at both 15 and 27 weeks.
Potential secondary outcomes are summarised in Add-
itional file 2. The adjusted mean differences indicate that
the BRiMS group improved more at 15 and 27 weeks
relative to the usual care group in most proposed out-
come measures; however, all adjusted between-group
mean differences were smaller than established MCID
(where available), with wide 95% confidence intervals.
N/A not available, Unadjusted the mean difference be-
tween the allocated groups (BRiMS-usual care) with 95%
confidence interval for potential primary outcomes. Ad-
justed each participants’ baseline score was subtracted
from their follow-up score, and we report the mean dif-
ference between the allocated groups (BRiMS-usual
care) with 95% confidence interval for potential primary
outcomes
Falls data
There was substantial variation between individual falls
reports over the 27-week study period (range 0–459
falls, as verified through telephone contact with the par-
ticipant). One participant accounted for over half the re-
ported falls in the usual care group; therefore, this
individual was classified as an outlier and removed from
the falls diary analyses presented, leaving a total of 715
falls.
Falls rates (see Table 4)
The rates of falls and injurious falls were lower in the
BRiMS than the usual care group; however, the confi-
dence intervals were wide and all included the null value
(one).
Indicative sample sizes for the anticipated definitive trial
The sample size calculations were undertaken for the
proposed primary outcome of MSWS-12v2 at the pri-
mary endpoint of 27 weeks, to detect an improvement of
5.2 units [33] at the two-sided, 5% significance level with
90% power. Sample sizes were also adjusted for loss to
follow-up rate of 70%.
As the definitive trial would be an individually rando-
mised group treatment trial [36], the analysis would use a
multi-level modelling approach, including adjustment for
the baseline MSWS-12v2 score and allowing for the par-
tially clustered data. It is assumed that participants allo-
cated to the intervention arm would be clustered within
small groups (~ 5 participants), whilst participants allo-
cated to the usual care arm would not be clustered. There-
fore, the indicative sample size calculations account for a
potential ‘group’ effect by incorporating the intra-cluster
correlation (ICC) [36, 37]. Given that the intervention is
standardised and that the number of BRiMS group-based
sessions is small, it is assumed the ICC will be small. How-
ever to account for any potential clustering effect, the base
case assumes a conservative ICC of 0.05.
In this feasibility study, the point estimate of the SD of
MSWS12-v2 at 27 weeks was 19.4 units, with one-sided
80% upper bound of 21.5. However, a slightly inflated SD
of MSWS12-v2 of 23 units is assumed, based on pooling
estimates from previous relevant studies [38, 39].
Correlation estimates for MSWS12-v2 between baseline
and follow-up in the SWIMS project were 0.85–0.89 [40],
indicating an adjustment for this correlation should be in-
cluded in the sample size calculation. The correlation in
this study was 0.59, with one-sided 80% lower bound of
0.50. Therefore, the base case assumes a correlation of 0.6.
The sample size calculations were performed in STATA
using the clsampsi [37] command. The base case indicated
a recruitment target of 836 participants in order to follow
up 584 participants. Additional file 3 shows indicative
sample sizes under a range of assumptions and shows that
Gunn et al. Pilot and Feasibility Studies             (2021) 7:2 Page 8 of 15
Table 2 Summary statistics of participants’ clinical and demographic data at baseline







Mean (SD) 60.0 (8.5) 58.7 (10.8) 59.3 (9.7)
[Min–max] [46.0–81.0] [34.0–80.0] [34.0–81.0]
Gender
Male 9 (34.6) 10 (33.3) 19 (33.9)
Female 17 (65.4) 20 (66.7) 37 (66.1)
Living arrangementsc
Alone 9 (34.6) 7 (23.3) 16 (28.6)
Spouse/partner 15 (57.7) 19 (63.3) 34 (60.7)
Parent/s 1 (3.8) 2 (6.7) 3 (5.4)
Child/ren 4 (15.4) 4 (13.3) 8 (14.3)
Other 1 (3.3) 1 (1.8)
Occupation status
Unemployed 1 (3.8) 2 (6.7) 3 (5.4)
Part-time work 4 (15.4) 2 (6.7) 6 (10.7)
Full-time work 2 (7.7) 1 (3.3) 3 (5.4)
Age retired 5 (19.2) 5 (16.7) 10 (17.9)
Medically retired 14 (53.8) 19 (63.3) 33 (58.9)
EDSSb
Median (LQ-UQ) 6.0 (6.0–6.5) 6.5 (6.0–6.5) 6.3 (6.0–6.5)










Incontinence (previous 4 weeks)
Not at all 14 (53.8) 13 (43.3) 27 (48.2)
Once 1 (3.8) 3 (10) 4 (7.1)
2 to 4 times 3 (11.5) 7 (23.3) 10 (17.9)
>Weekly 5 (19.2) 3 (10) 8 (14.3)
Daily 3 (11.5) 4 (13.3) 7 (12.5)
Three-month fall history
Not fallena 1 (3.3) 1 (1.8)
Twice 7 (26.9) 5 (16.7) 12 (21.4)
3–5 times 11 (42.3) 13 (43.3) 24 (42.9)
More often 8 (30.8) 11 (36.7) 19 (33.9)
Indoor walking aidsc
1 stick/crutch 9 (34.6) 13 (43.3) 22 (39.3)
2 sticks/crutches 5 (19.2) 4 (13.3) 9 (16.1)
Walker/frame 8 (30.8) 12 (40) 20 (35.7)
Wheelchair 4 (15.4) 4 (13.3) 8 (14.3)
Outdoor walking aidsc
1 stick/crutch 17 (65.4) 18 (60) 35 (62.5)
2 sticks/crutches 10 (38.5) 7 (23.3) 17 (30.4)
Walker/frame 9 (34.6) 14 (46.7) 23 (41.1)
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the main drivers of the total sample size required are the
standard deviation and the correlation between baseline
and follow-up of MSWS-12v2 scores.
Health economics analysis
Methods used for economic analysis proved practical and
feasible. The health economics resource use question-
naires and therapist contact sheets had completion rates
greater than 98% for all those who attended assessments.
The mean cost per person for delivery of the BRiMS
programme was £323. This is based on data collected on
staff time by type of contact and staff type (NHS Band
7), collected within-study, aligned with published unit
cost data; a mean of one clinic visit, one home visit, 5.26
online contacts and three group contacts. See the full
project report [11] for further detail.
Detailed data on resource use is included in Additional
file 4. Participants reported relatively modest levels of re-
source use over the study period, mostly focussed around
items of primary and secondary care. There was little
medication use reported by participants, which aligned
with the study inclusion criteria, and was consistent with
expectations as all participants had progressive MS. Esti-
mated medication costs were associated with one person
in each group reporting use of disease modifying therapy
over the 27-week follow-up (for 25 weeks in the usual care
group, and 6 weeks in the intervention group).
There was consistent reporting of informal care
provision, with the reported mean hours per week similar
across groups (24–25 h per week), estimated at a weekly
cost of approximately £445 per participant; this being a
relatively large cost component, currently provided via un-
paid informal care inputs. Data on time off work by
friends/relatives to support the participant was also cap-
tured, with no reports in the BRiMS group, and one par-
ticipant in the usual care group reporting 13 days (mean
of 0.59 days/participant in the usual care group).
As reported in detail elsewhere [11], there was some re-
dundancy in the questionnaire items (i.e. no or minimal
reports of resource use), which suggests a potential to re-
duce the questionnaire length in a future definitive trial.
Health state values (EQ-5D, MSIS-8D) and quality adjusted
life-years (QALYs)
The data collection to inform assessment of health state
values was effective, with low levels of data loss. Table 5
summarises the estimated health state values and QALY
estimates.
Discussion
The results from this feasibility study inform the design
of a future definitive randomised controlled trial of this
exercise and education programme to improve safe mo-
bility and reduce falls in people with progressive MS.
Feasibility
Our pre-specified thresholds for recruitment, retention
and data collection were satisfied [9]. Significant variabil-
ity was identified in recruitment rates depending on the
approach used. Previous studies have emphasised the
need for a multi-faceted recruitment strategy [41];
Table 2 Summary statistics of participants’ clinical and demographic data at baseline (Continued)






Wheelchair 12 (46.2) 15 (50) 27 (48.2)
Number of medications
Median (LQ–UQ) 4 (2–7) 5 (2–7) 4 (2–7)
[Min–Max] [0–10] [0–17] [0–17]
Current co-morbiditiesc
COPD/asthma 1 (3.8) 2 (6.7) 3 (5.4)
Coronary heart disease/hypertension 1 (3.8) 1 (3.3) 2 (3.6)
Depression/anxiety 4 (15.4) 7 (23.3) 11 (19.6)
Diabetes 1 (3.8) 1 (3.3) 2 (3.6)
Migraine 3 (11.5) 1 (3.3) 4 (7.1)
Osteoarthritis 3 (11.5) 6 (20) 9 (16.1)
Osteoporosis 5 (19.2) 2 (6.7) 7 (12.5)
Other 10 (38.5) 11 (36.7) 21 (37.5)
Other neurological condition 1 (3.8) 1 (3.3) 2 (3.6)
aThere was no option for participants to report falling once
bExpanded disability status scale; SDMT symbol digit modalities test
c Participants could enter in multiple options; therefore percentages may not add up to 100
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however, our results highlight the importance of a per-
sonal approach by clinicians or research staff.
Overall loss to follow-up was within the 20% anticipated.
There was a discrepancy between retention rates in the two
arms of the study, and in particular, the dropout rate in the
intervention group was higher than anticipated. In com-
parison, a review of 26 exercise intervention studies re-
ported combined dropout rates of 15% and 16% for
intervention and usual care groups respectively [42]. We
hypothesise that our higher dropout rate in the intervention
group may be associated with expectations of the BRiMS
programme. Further exploration of this aspect is required,
supporting the notion that feasibility testing is only one
stage in the cycle of developing complex interventions [43].
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22 40.0 (26.8) 22 43.3 (22.6) 3.3 (− 11.8 to 18.4) − 0.4 (− 9.9 to 9)
[0.0–93] [7.0–81]
MSWS MS walking scale, MSIS MS impact scale
aDecrease in score indicates improvement
bIncrease in score indicates improvement










Falls (rate per person per year)
Rate 38.1 39.1 21.9 27.0
Rate ratio (95% CI)a 0.97 (0.40 to 2.22) 0.81 (0.41 to 2.26)
Injurious falls (rate per person per year)
Rate 3.8 7.1 2.2 4.9
Rate ratio (95% CI)a 0.53 (0.40 to 2.21) 0.44 (0.41 to 2.23)
aBootstrapped 95% confidence intervals (CI)
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Participant characteristics
In recognition of the prevalence of comorbidity in MS, our
recruitment criteria set out to be as inclusive as possible,
and the sample characteristics were in line with publica-
tions in this field [44]. Whilst the allocation between groups
was similar for most MS-related characteristics, the differ-
ing distribution of some (such as EDSS, anxiety/depression
and cognition) could potentially affect outcomes, as evi-
denced by differences in baseline measures between the
groups (e.g. MSWS-12v2, MiniBEST). This suggests that
randomisation in a future definitive trial may require strati-
fication by these characteristics, and that potential sub-
group analyses should be considered when developing an a
priori statistical analysis plan. The baseline characteristics
also highlight that our sample was more severely balance
and mobility impaired in comparison to a number of other
studies with similar sample EDSS levels [21, 45]. For ex-
ample, Gijbels et al. [46] report mean walking distances of
104 metres in the two minute walking test in a sample of
21 people with an EDSS between 4.5–6.5. In comparison,
on average, our sample walked around 53 m at baseline. In
addition, our sample reported higher levels of concern (as
measured by the FESi) than other MS populations of mixed
MS subtypes, although this is perhaps not surprising given
their falls history and progressive MS [47].
Proposed primary outcome measure
A key aim was to obtain data to inform the selection of a
primary outcome measure for the definitive trial. The major
consequence of falling for the individual is increasing
mobility impairment, activity curtailment and loss of
confidence [8, 48, 49]. Therefore, based on the existing evi-
dence base, together with the results from this feasibility
study, we recommend that the primary outcome for a de-
finitive trial is the MSWS-12v2 [16]. Whilst a direct meas-
ure of injurious falls would be our favoured option given its
clinical importance, our hesitancy in recommending this
outcome is the recognised issues with the validity and
reliability of falls diary data [50, 51], as evidenced by the
problems with data completeness and accuracy we also ex-
perienced. If these issues can be resolved, then injurious
falls should be re-considered as a primary outcome in a de-
finitive trial. However, it is recognised that this would likely
require a significantly larger sample size.
Health economics data
Methods for collection of data (costs, outcomes) for a
future economic evaluation were feasible and few chal-
lenges were faced in relation to this. The results high-
light the relatively modest resource use of ‘formal’ health
and care resources by the study participants, and the
high use of ‘informal’ care and support. Our study is un-
able to determine if this pattern is through necessity
(e.g. due to lack of resources) or choice; however, the
findings reflect the importance of collecting comprehen-
sive resource use data capturing both formal and infor-
mal care and support. The estimated health state values
and QALY estimates are lower when using the MSIS-
8D, and further research is recommended to consider
why this may be (for example, being linked to specific
domains of health-related QoL that may not be covered
Table 5 Health state values and QALYs
Usual care BRiMS
Mean (SD) Min Max N Mean (SD) Min Max N
Baseline data:
EQ5D-3L 0.58 (0.16) 0.04 0.77 26 0.54 (0.17) − 0.04 0.88 29
EQ5D-5L 0.66 (0.20) 0.07 0.89 26 0.63 (0.17) 0.22 0.95 29
MSIS-8D 0.51 (0.21) 0.08 0.80 26 0.49 (0.15) 0.21 0.76 30
Week 15 data:
EQ5D-3L 0.60 (0.18) 0.20 0.91 24 0.59 (0.17) − 0.00 0.88 25
EQ5D-5L 0.69 (0.18) 0.19 0.95 24 0.67 (0.17) 0.26 0.95 25
MSIS-8D 0.54 (0.20) 0.13 0.82 24 0.56 (0.16) 0.22 0.83 25
Week 27 data:
EQ5D-3L 0.59 (0.25) − 0.13 0.91 22 0.57 (0.11) 0.30 0.77 22
EQ5D-5L 0.67 (0.25) 0.05 0.95 22 0.65 (0.15) 0.38 0.89 22
MSIS-8D 0.56 (0.19) 0.08 0.88 22 0.54 (0.17) 0.18 0.77 22
Estimated QALYs (over 27 weeks):
EQ5D-3L 0.30 (0.08) 0.13 0.43 22 0.30 (0.05) 0.20 0.42 22
EQ5D-5L 0.34 (0.09) 0.11 0.46 22 0.34 (0.07) 0.22 0.47 22
MSIS-8D 0.28 (0.10) 0.09 0.42 22 0.29 (0.06) 0.20 0.40 22
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fully by the EQ-5D). However, the MSIS-8D indicates
potential to show differences between groups over time.
Strengths and limitations
A key strength of this feasibility study is that it used ro-
bust methodology, with comprehensive step-by-step
documentation and evaluation of our processes, deci-
sions and outcomes. However, there were some limita-
tions. Most notably, despite adhering to best-practice
recommendations [15] and with previous high return
rates using similar methods [5, 52], the low return rate
of the self-report paper-based falls diaries means that
our falls data must be interpreted with caution. Our re-
sults highlight the need to find a valid and reliable
method of collecting these data before falls can be con-
sidered as a potential primary outcome. Further, our as-
sumption that if participants did not return a fall diary
they did not fall, errs on the side of underestimating
falls. In addition, the participants were only followed up
for 3 months, and hence operational issues (such as
study retention) and clinical outcomes are unknown for
a longer follow-up period.
Conclusions and recommendations
This study assessed the feasibility of undertaking a de-
finitive trial to compare BRiMS plus usual care to usual
care alone in a sample of people with SPMS who re-
ported themselves as falling. We have demonstrated the
study procedures to be feasible. Retention, programme
engagement and outcome completion rates were all suf-
ficient to satisfy our a priori progression criteria. Chal-
lenges were experienced in some areas, such as the
completion of daily self-report fall diaries. A future trial
should consider alternative methods of collecting these
data. Estimated sample sizes for a definitive trial with
MSWS-12v2 as the primary outcome range from 575 to
990 participants.
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